Per‐Olof Lundgren
Papers
1
Total Citations
19
H-Index
1
About
Per-Olof Lundgren is a leading urologic oncologist whose research centers on testicular cancer, particularly the refinement of surgical treatments to reduce long-term toxicity. His major contribution lies in championing primary retroperitoneal lymph node dissection (RPLND) as a viable alternative to chemotherapy for low-volume metastatic seminoma. This work, exemplified by his landmark 2024 population-based study from the Swedish Norwegian Testicular Cancer Group (19 citations), directly addresses the critical need to spare young patients from the lifelong side effects of cytotoxic therapy. By demonstrating the oncological efficacy and safety of RPLND in a real-world cohort, Lundgren is reshaping treatment paradigms for seminoma. His research bridges the gap between surgical innovation and survivorship, offering a path to cure without the burden of chemotherapy. With a career dedicated to evidence-based surgical oncology, Lundgren’s impact extends beyond citation counts; he is actively redefining standards of care for testicular cancer, making him a pivotal figure in the movement toward de-escalation of treatment in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1